ALX Oncology HoldingsALXO +7.52%27 EV-to-FCF is -2.37 as of Jul. 07, 2026. GuruFocus rates ALXO with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 329 Biotechnology companies, ALX Oncology Holdings ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ALX Oncology Holdings's Enterprise Value is $185.76 Mil.
ALX Oncology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-78.33 Mil. Therefore, ALX Oncology Holdings's EV-to-FCF for today is -2.37.
The historical rank and industry rank for ALX Oncology Holdings's EV-to-FCF or its related term are showing as below:
ALXO'
s EV-to-FCF Range Over the Past 10 Years
Min: -86.37 Med: 2.19 Max: 11.99
Current: -2.37
During the past 8 years, the highest EV-to-FCF of ALX Oncology Holdings was 11.99. The lowest was -86.37. And the median was 2.19.
ALXO's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs ALXO: -2.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ALX Oncology Holdings's PE Ratio (TTM) for today is calculated as:
ALX Oncology Holdings's share price for today is $2.355.
ALX Oncology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ALX Oncology Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's EV-to-FCF falls into.
ALX Oncology Holdings's current Enterprise Value is $185.76 Mil.
ALX Oncology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALXO) has a EV-to-FCF of -2.37 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ALX Oncology Holdings and its competitors. According to the industry distribution chart, ALX Oncology Holdings ranks #999999 out of 329 companies in the Biotechnology industry.
Is ALX Oncology Holdings' EV-to-FCF too high?
ALX Oncology Holdings' current EV-to-FCF is -2.37. Based on the distribution chart, ALX Oncology Holdings ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ALX Oncology Holdings has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' EV-to-FCF compare to LYEL and ARMP?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #999999 out of 329 companies for EV-to-FCF. This places ALX Oncology Holdings in the lower half of its industry. The industry median EV-to-FCF is 16.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ALX Oncology Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALX Oncology Holdings's current EV-to-FCF is -2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current EV-to-FCF of -2.37. The current EV-to-FCF is -2.37. ALX Oncology Holdings' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current EV-to-FCF is -2.37 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
27GF Score
Get the complete analysis for ALXO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
